Please login to read the full article.
Scrip Regulatory Affairs
Developing a common benefit-risk assessment methodology for medicines - a progress report
09 December 2011
Stuart Walker, Neil McAuslane and Lawrence Liberti
Please login to read the full article.
Not a subscriber ? Request a FREE Trial
Subscribe to Regulatory Affairs Pharma
RELATED CONTENT
NEWS
Scrip Regulatory Affairs News
- US FDA consults on new framework for classifying significant drug post-market safety issues
- BEMA benchmarking scheme for EU drug agencies enters cycle III; medical devices might be on horizon
- GHTF successor IMDRF to expand membership; shortlists work priorities at inaugural meeting
- EMA lays out drug safety priorities for 2012
Other Informa News
ANALYSIS
Regulatory Affairs Pharma Analysis
Other Informa Analysis
EDITORIALS
Regulatory Affairs Pharma Editorials
Other Informa Editorials
FEATURES
Regulatory Affairs Pharma Features
Other Informa Features
COMMENT
Regulatory Affairs Pharma Comment
Other Informa Comments
